Your voice is powerful. We're asking you to Speak Out and tell us why Australians having access to the latest medicines for hepatitis C is important to you. Currently there are medicines approved in other countries that can cure hepatitis C in as little as 12 weeks. Australians are still waiting for these medicines to be affordable. We need to show the government and the pharmaceutical companies why it is important. That's where you come in!

What can you do? You can complete our online form and share your story, in your words, about hepatitis C and what a cure will mean for you, or someone you love. We will post a quote from you (including your first name only and state/territory only) on this website thereby you can share your story with others and decision makers.

So... grab a cuppa, click on the link below and take a few moments to tell us your story.

Hepatitis Australia

Hepatitis
Australia is the national peak body representing the interests of Australians
living with, or at risk, of viral hepatitis.
Our members are the eight state and territory hepatitis organisations.
Through national leadership, advocacy, and strong partnerships our mission is
to ensure effective action on hepatitis B and hepatitis C to meet the needs of
all Australians.

LATEST NEWS

Curative treatment uptake for chronic hepatitis C (CHC) is generally at its lowest in local areas where prevalence of the virus is at its highest, according to the inaugural Hepatitis C Mapping Project National Report 2016 recently launched in Melbourne.

Australia will not achieve the goal of eradicating hepatitis C without further action to ensure patients are identified and treated.

Speaking with PharmaDispatch following her appointment as president of Hepatitis Australia, Felicity McNeill PSM, said so much positive work has been done, with thousands of people cured, but all stakeholders must come together to address the fact treatment rates are in decline.

Someone very familiar to the pharmaceutical sector has been appointed president of Hepatitis Australia. Felicity McNeill PSM, who for almost five years served as first assistant secretary of the Pharmaceutical Benefits Division, has been appointed to the part-time role of president of the national peak body focussed on representing Australians living with hepatitis B and C.

After three days of discussing, debating and formulating solutions together, the World Hepatitis Summit 2017 drew to a close on Friday. Over 900 delegates from 110 countries descended on São Paulo, Brazil all armed with one goal: the elimination of viral hepatitis. At the event, double the size of the inaugural World Hepatitis Summit 2015, important steps were made to reach this goal by 2030.

Hepatitis Australia’s Acting CEO Kevin Marriott told PharmaDispatch the organisation is concerned over the recent fall in [hepatitis C treatment] uptake and it is now working to ensure as many people as possible access treatment.

Responding to the Kirby Institute’s report, Hepatitis Australia’s Acting CEO Kevin Marriott said that Australia needs to capitalise on this early success to ensure all Australians impacted by viral hepatitis have access to effective treatment and care.

Following an energetic dinner where delegates showed off their samba moves, the second day of the World Hepatitis Summit was dedicated to strategic directions 2 and 3, which cover the issues of "interventions for impact" and "delivering for equity" - “the what and the how” of elimination.